GlassScriptPhysician profile
Michael T Warhurst
NPI 1356791743
$2,495.55
in general payments reported to CMS, 2019-2025
12 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2024: $1,841 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150 · Travel and Lodging: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.35 |
| Travel and Lodging | $934.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,523.85 | 2024-2025 | Synchromedii, Intellis Adaptivestim |
| Curonix LLC | $364.62 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $210.35 | 2019 | |
| Medtronic USA, INC. | $165.91 | 2019 | |
| Tersera Therapeutics LLC | $48.56 | 2024-2025 | Prialt |
| Globus Medical, INC. | $43.73 | 2025 | Senza |
| Abbott Laboratories | $35.22 | 2024 | Eterna |
| Pacira Pharmaceuticals Incorporated | $26.37 | 2024 | Iovera, Zilretta, Exparel |
| Spr Therapeutics, INC | $23.46 | 2025 | Sprint Pns System |
| Edwards Lifesciences Corporation | $19.25 | 2019 | |
| Nalu Medical, INC. | $19.01 | 2024 | Nalu Neurostimulation System |
| Amgen INC. | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Warhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.